Olezarsen sodium is under clinical development by Ionis Pharmaceuticals and currently in Phase III for Familial Chylomicronemia (Type I Hyperlipoproteinemia). According to GlobalData, Phase III drugs for Familial Chylomicronemia (Type I Hyperlipoproteinemia) does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Olezarsen sodium LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Olezarsen sodium overview
AKCEA-APOCIIILRx is under development for the treatment of severe high triglycerides (SHTG) and high triglycerides with type 2 diabetes, familial chylomicronemia syndrome and atherosclerotic cardiovascular disease. It is administered subcutaneously. The drug candidate is an GalNAc3 conjugated antisense oligonucleotide which acts by targeting the apolipoprotein C-III protein (ApoC-III). The development of drug candidate is based on ligand-conjugated antisense (LICA) technology.
Ionis Pharmaceuticals overview
Ionis Pharmaceuticals (Ionis), formerly Isis Pharmaceuticals, focuses on the discovery and development of RNA-targeted drugs. The company develops medicines to treat various diseases including cancer, pulmonary, cardiovascular diseases, neurological and infectious diseases. Its major products include Spinraza for spinal muscular atrophy, Tegsedi for neuropathy and Waylivra for familial chylomicronemia syndrome. Ionis also has a pipeline of products in different phases of clinical trials. It develops products based on its proprietary antisense technology. The company partnered with other pharmaceutical companies to develop a range of products in different therapeutic areas. The company sells its products in North America and Europe. Ionis is headquartered in Carlsbad, California, the US.
For a complete picture of Olezarsen sodium’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
